TABLE 4.
Univariate and multivariate analyses of the effect of GAL3 expression on overall survival (OS)
| Factors | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p‐value | HR | 95% CI | p‐value | |
| GAL3 expression | ||||||
| High vs. low | 2.296 | 1.156–4.562 | 0.018 | 1.708 | 0.831–3.513 | 0.146 |
| Age, years | ||||||
| ≥60 vs. <60 | 1.562 | 0.790–3.088 | 0.2 | Not included | ||
| Sex | ||||||
| Male vs. female | 1.379 | 0.732–2.599 | 0.32 | Not included | ||
| Smoking status | ||||||
| Smoker vs. never smoker | 0.784 | 0.411–1.495 | 0.46 | Not included | ||
| Histological type | ||||||
| AD vs. non‐AD | 0.332 | 0.130–0.851 | 0.022 | 0.485 | 0.180–1.311 | 0.154 |
| p‐TNM stage | ||||||
| Stage III vs. stage II | 3.612 | 1.411–9.242 | 0.007 | 2.948 | 1.136–7.652 | 0.026 |
| Chemotherapeutic regimen | ||||||
| CDDP vs. CBDCA based | 0.653 | 0.335–1.274 | 0.212 | Not included | ||
| Number of treatment cycles | ||||||
| 3–4 vs. 1–2 | 0.605 | 0.267–1.372 | 0.229 | Not included | ||
Note: All analyses were performed using Cox proportional hazard regression.
Abbreviations: AD, adenocarcinoma; CBDCA, carboplatin; CDDP, cisplatin; 95% CI, 95% confidence interval; HR, hazard ratio; non‐AD, nonadenocarcinoma.